ELCC 2025
The European Lung Cancer Congress 2025 took place in Paris, France.
Advertisement
Suresh S. Ramalingam, MD, FACP, FASCO, presented the data during a proffered paper session at ELCC 2025.
Marina Garassino, MD, presented results from the phase 2 portion of the trial at the European Lung Cancer Congress.
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Myung-Ju Ahn, MD, PhD, presented data from the study during the first proffered paper session of ELCC 2025.
Nicolas Girard, MD, PhD, of Institut Curie, presented the findings from expansion cohorts of the study at ELCC 2025.
Xiuning Le, MD, PhD, presented results from the ORCHARD trial at ELCC 2025.
The award recognizes his "exceptional contributions to thoracic oncology research and education."
Amivantamab plus lazertinib showed a statistically significant improvement in OS compared with osimertinib.
Final overall survival data from the phase 3 study demonstrated significant benefits for patients with EGFR-mutated aNSCLC.
Dr. Liu shares what he's looking forward to during the European Lung Cancer Congress, which will be held March 26-29.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.